Compared side by side
Cagrilintide vs pramlintide: how they differ
The short answer
Both are copies of amylin, the fullness hormone the pancreas releases with insulin: pramlintide, the first amylin drug, lasts under an hour and is injected right before each main meal, while cagrilintide carries a fatty-acid chain that stretches its half-life to about a week. Pramlintide was FDA-approved in 2005, as Symlin, as an add-on to mealtime insulin in diabetes, and its US pens are being discontinued; cagrilintide isn’t approved on its own and is the amylin half of Novo Nordisk’s CagriSema. In obesity trials without insulin, pramlintide’s weight loss was about 6 to 7 kg beyond placebo at a year, and cagrilintide’s higher doses led to about 10–12% weight loss on their own.
Side by side
| Compared | Cagrilintide | Pramlintide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Cagri, AM833, NNC0174-0833 | Symlin, SymlinPen, AC137 |
| What it is | A long-acting version of amylin, the fullness hormone the pancreas releases alongside insulin, given as a weekly shot. | The first amylin drug (Symlin), approved in 2005 for people with diabetes who use mealtime insulin: a shot before each main meal that slows digestion and makes people feel full sooner. |
| How it works | Long-acting, lipidated analogue of amylin, the satiety hormone the pancreas releases with insulin. It activates amylin receptors and the calcitonin receptor (a non-selective amylin agonist); amylin promotes fullness, slows stomach emptying and holds back glucagon after meals. A fatty-acid chain stretches its half-life to about a week, so it is a weekly shot, usually run beside a GLP-1. Not approved on its own: it is the amylin half of Novo Nordisk's CagriSema. | A synthetic copy of amylin, the hormone the pancreas releases with insulin after a meal, with three of its amino acids swapped for proline. It slows stomach emptying, blunts the after-meal rise in glucagon and acts in the brain to make people feel full, so they eat less. It lasts under an hour in the body, so it is injected right before each main meal. FDA-approved in 2005 as an add-on to mealtime insulin in type 1 and type 2 diabetes; it is the older, short-acting relative of cagrilintide, and its US pens are being discontinued. |
| Commonly reported | Feeling full sooner and portions shrinking, with nausea or constipation after step-ups and some injection-site reactions. It is not approved on its own. | Early fullness and nausea in the first weeks. It is the short-acting ancestor of weekly cagrilintide, and its US pens are being discontinued. |
| Studied range | Research range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation. | FDA label: 15–120 mcg, starting dose 15 mcg. |
| How often | Weekly | 2–3x daily SubQ, right before major meals |
| Half-life | ~1 week (measured in people: 159–195 hours in a phase 1b trial) | ~0.8 hours (48 minutes, FDA label) |
| Route | SubQ injection | SubQ injection |
| Typical run | Trials run it continuously: 26 weeks in phase 2, 68 weeks in phase 3. Community use is mostly as a weekly add-on to a GLP-1. | FDA-approved for ongoing use with mealtime insulin; its placebo-controlled trials ran 26 to 52 weeks. If it is stopped (surgery, illness), the label restarts it with the same start-up steps. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, constipation, diarrhea, injection-site reactions | Nausea, loss of appetite, vomiting, headache, fatigue, dizziness, low blood sugar (with insulin) |
- Category
- CagrilintideMetabolic & GLP-1
- PramlintideMetabolic & GLP-1
- Also known as
- CagrilintideCagri, AM833, NNC0174-0833
- PramlintideSymlin, SymlinPen, AC137
- What it is
- CagrilintideA long-acting version of amylin, the fullness hormone the pancreas releases alongside insulin, given as a weekly shot.
- PramlintideThe first amylin drug (Symlin), approved in 2005 for people with diabetes who use mealtime insulin: a shot before each main meal that slows digestion and makes people feel full sooner.
- How it works
- CagrilintideLong-acting, lipidated analogue of amylin, the satiety hormone the pancreas releases with insulin. It activates amylin receptors and the calcitonin receptor (a non-selective amylin agonist); amylin promotes fullness, slows stomach emptying and holds back glucagon after meals. A fatty-acid chain stretches its half-life to about a week, so it is a weekly shot, usually run beside a GLP-1. Not approved on its own: it is the amylin half of Novo Nordisk's CagriSema.
- PramlintideA synthetic copy of amylin, the hormone the pancreas releases with insulin after a meal, with three of its amino acids swapped for proline. It slows stomach emptying, blunts the after-meal rise in glucagon and acts in the brain to make people feel full, so they eat less. It lasts under an hour in the body, so it is injected right before each main meal. FDA-approved in 2005 as an add-on to mealtime insulin in type 1 and type 2 diabetes; it is the older, short-acting relative of cagrilintide, and its US pens are being discontinued.
- Commonly reported
- CagrilintideFeeling full sooner and portions shrinking, with nausea or constipation after step-ups and some injection-site reactions. It is not approved on its own.
- PramlintideEarly fullness and nausea in the first weeks. It is the short-acting ancestor of weekly cagrilintide, and its US pens are being discontinued.
- Studied range
- CagrilintideResearch range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation.
- PramlintideFDA label: 15–120 mcg, starting dose 15 mcg.
- How often
- CagrilintideWeekly
- Pramlintide2–3x daily SubQ, right before major meals
- Half-life
- Cagrilintide~1 week (measured in people: 159–195 hours in a phase 1b trial)
- Pramlintide~0.8 hours (48 minutes, FDA label)
- Route
- CagrilintideSubQ injection
- PramlintideSubQ injection
- Typical run
- CagrilintideTrials run it continuously: 26 weeks in phase 2, 68 weeks in phase 3. Community use is mostly as a weekly add-on to a GLP-1.
- PramlintideFDA-approved for ongoing use with mealtime insulin; its placebo-controlled trials ran 26 to 52 weeks. If it is stopped (surgery, illness), the label restarts it with the same start-up steps.
- Evidence
- CagrilintideEstablished: clinical trials or FDA-approved use exists
- PramlintideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- CagrilintideNausea, constipation, diarrhea, injection-site reactions
- PramlintideNausea, loss of appetite, vomiting, headache, fatigue, dizziness, low blood sugar (with insulin)
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Cagrilintide
- Day 1–28 · 0.25 mg The 0.25 mg start
- Day 29–364 · 0.5 mg 0.5 mg, the second step
- Day 57–364 · 1 mg 1 mg, the middle step
- Day 85–364 · 1.7 mg 1.7 mg, the step before 2.4 mg
- Day 113+ · 2.4 mg 2.4 mg, the phase 3 dose
Pramlintide
- Day 1–14 · 15 mcg The 15 mcg start (type 1)
- Day 1–30 · 60 mcg 60 mcg, a start and a top dose
- Day 4–365 · 120 mcg 120 mcg, the type 2 dose
- Day 14–365 What it did for weight without insulin
Questions people ask
How long do cagrilintide and pramlintide last?
The half-life of cagrilintide is ~1 week (measured in people: 159–195 hours in a phase 1b trial). The half-life of pramlintide is ~0.8 hours (48 minutes, FDA label).
How often are cagrilintide and pramlintide taken?
Cagrilintide: weekly. Route: SubQ injection. Pramlintide: 2–3x daily SubQ, right before major meals. Route: SubQ injection.
How are cagrilintide and pramlintide dosed in research?
The research range for cagrilintide is 0.25–2.4 mg, with a 0.25 mg starting dose. Studied in research — not a recommendation. The FDA label range for pramlintide is 15–120 mcg, with a 15 mcg starting dose.
What are the common side effects of cagrilintide and pramlintide?
For cagrilintide, the library lists: nausea, constipation, diarrhea, injection-site reactions. For pramlintide: nausea, loss of appetite, vomiting, headache, fatigue, dizziness, low blood sugar (with insulin).